Literature DB >> 9600986

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

M P Lambert1, A K Barlow, B A Chromy, C Edwards, R Freed, M Liosatos, T E Morgan, I Rozovsky, B Trommer, K L Viola, P Wals, C Zhang, C E Finch, G A Krafft, W L Klein.   

Abstract

Abeta1-42 is a self-associating peptide whose neurotoxic derivatives are thought to play a role in Alzheimer's pathogenesis. Neurotoxicity of amyloid beta protein (Abeta) has been attributed to its fibrillar forms, but experiments presented here characterize neurotoxins that assemble when fibril formation is inhibited. These neurotoxins comprise small diffusible Abeta oligomers (referred to as ADDLs, for Abeta-derived diffusible ligands), which were found to kill mature neurons in organotypic central nervous system cultures at nanomolar concentrations. At cell surfaces, ADDLs bound to trypsin-sensitive sites and surface-derived tryptic peptides blocked binding and afforded neuroprotection. Germ-line knockout of Fyn, a protein tyrosine kinase linked to apoptosis and elevated in Alzheimer's disease, also was neuroprotective. Remarkably, neurological dysfunction evoked by ADDLs occurred well in advance of cellular degeneration. Without lag, and despite retention of evoked action potentials, ADDLs inhibited hippocampal long-term potentiation, indicating an immediate impact on signal transduction. We hypothesize that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer's disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Abeta-derived diffusible ligands acting upon particular neural signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600986      PMCID: PMC27787          DOI: 10.1073/pnas.95.11.6448

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  67 in total

1.  Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain.

Authors:  J Busser; D S Geldmacher; K Herrup
Journal:  J Neurosci       Date:  1998-04-15       Impact factor: 6.167

2.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.

Authors:  J T Jarrett; E P Berger; P T Lansbury
Journal:  Biochemistry       Date:  1993-05-11       Impact factor: 3.162

3.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

4.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

Authors:  J Ghiso; E Matsubara; A Koudinov; N H Choi-Miura; M Tomita; T Wisniewski; B Frangione
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

5.  7,12-Dimethylbenz[a]anthracene activates protein-tyrosine kinases Fyn and Lck in the HPB-ALL human T-cell line and increases tyrosine phosphorylation of phospholipase C-gamma 1, formation of inositol 1,4,5-trisphosphate, and mobilization of intracellular calcium.

Authors:  M M Archuleta; G L Schieven; J A Ledbetter; G G Deanin; S W Burchiel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state.

Authors:  C J Pike; D Burdick; A J Walencewicz; C G Glabe; C W Cotman
Journal:  J Neurosci       Date:  1993-04       Impact factor: 6.167

7.  Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Authors:  P Seubert; C Vigo-Pelfrey; F Esch; M Lee; H Dovey; D Davis; S Sinha; M Schlossmacher; J Whaley; C Swindlehurst
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

8.  The protein tyrosine kinase, fyn, in Alzheimer's disease pathology.

Authors:  S K Shirazi; J G Wood
Journal:  Neuroreport       Date:  1993-04       Impact factor: 1.837

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice.

Authors:  S G Grant; T J O'Dell; K A Karl; P L Stein; P Soriano; E R Kandel
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

View more
  1199 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 2.  Amyloid diseases: abnormal protein aggregation in neurodegeneration.

Authors:  E H Koo; P T Lansbury; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

3.  Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice.

Authors:  T Wyss-Coray; C Lin; D A Sanan; L Mucke; E Masliah
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 4.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.

Authors:  P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 5.  Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo.

Authors:  S D Yan; A Roher; A M Schmidt; D M Stern
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

6.  A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.

Authors:  Yasuhiro Nakagami; Satoko Nishimura; Takako Murasugi; Isao Kaneko; Masaki Meguro; Shinji Marumoto; Hiroshi Kogen; Kazuo Koyama; Tomiichiro Oda
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

7.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

8.  An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies.

Authors:  Deborah A Ryan; Wade C Narrow; Howard J Federoff; William J Bowers
Journal:  J Neurosci Methods       Date:  2010-05-07       Impact factor: 2.390

Review 9.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

10.  Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility.

Authors:  Li Ling Lee; HyungHo Ha; Young-Tae Chang; Matthew P DeLisa
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.